A Radiomics Approach to Predict the Effect of Bevacizumab Plus Chemotherapy in Patients With Liver Metastases of Colorectal Cancer: A Prospective Multi-Centers Trial

Peking University People's Hospital1 site in 1 country300 target enrollmentOctober 2020

ConditionsColon Cancer Rectal Cancer Liver Metastases

DrugsBevacizumab

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Colon Cancer
Sponsor: Peking University People's Hospital
Enrollment: 300
Locations: 1
Primary Endpoint: estimated ORR
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.

Registry

clinicaltrials.gov

Start Date

October 2020

End Date

December 2023

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Peking University People's Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Colorectal carcinoma confirmed by pathological result.
•Liver metastasis confirmed by imaging studies.
•Treatment of bevacizumab combined with chemotherapy chosen by MDT team.
•Normal laboratory studies including liver\\renal\\bone marrow functions.
•Expected lifespan more than 3 months.

Exclusion Criteria

•Previous treatment of colorectal cancer with liver metastasis.
•Diagnosed with other malignancies.
•Couldn't finish the trial due to several reasons such as allergy to chemotherapy drugs\\pregnancy or lactation\\chronic heart disease\\unable to sustain further treatment.